Effects of decaffeinated green coffee extract supplementation on anthropometric indices, blood glucose, leptin, adiponectin and neuropeptide Y (NPY) in breast cancer survivors: a randomized clinical trial

Bahmannia, Mahsa; Heydari, Sahar; Azizzade, Maryam; Nasrollahzadeh, Javad; Rostom, S.; Naja, Farah; Sheikhi-Mobarakeh, Zahra; Hejazi, Jalal; Hejazi, Ehsan

doi:10.1039/d2fo00983h

Cited by 4 publications

(2 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent meta-analysis of eight trials found that GCE supplementation (dosage 50–1,200 mg/d, duration of 8–12 weeks) has no effect on CRP ( 19 ). However, based on the results of this meta-analysis, GCE supplementation has a decreasing effect on tumor necrosis factor alpha (TNF-α) as an inflammatory biomarker ( 37 ). CGA, by increasing the expression of genes encoding enzymes, including glutathione peroxidase and superoxide dismutase, exerts reducing effects on oxidative stress ( 8 ).…”

Section: Discussionmentioning

confidence: 99%

Effects of green coffee aqueous extract supplementation on glycemic indices, lipid profile, CRP, and malondialdehyde in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial

Khalili-Moghadam,

Hedayati,

Golzarand

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

Background/objectivesStudies have reported the health benefits of green coffee extract (GCE) in experimental models. In the current study, we aimed to determine whether supplementation with GCE improves glycemic indices, inflammation, and oxidative stress in patients with type 2 diabetes (T2D).Methods and study designThis randomized, double-blind, placebo-controlled trial included 44 patients (26 male and 18 female) with T2D and overweight/obesity. After blocked randomization, patients received either capsules containing 400 mg GCE twice per day (n = 22) or a placebo (n = 22) and were followed for 10 weeks. In this study, glycemic indices, lipid profiles, anthropometric examinations, blood pressure, high-sensitivity C-reactive protein (hs-CRP), and malondialdehyde (MDA) were measured twice; at baseline and at the end of the study.ResultsAfter 10 weeks of supplementation, GCE supplementation significantly reduced body weight (p = 0.04) and body mass index (BMI) (p = 0.03) compared to the placebo. The intention-to-treat (ITT) analysis indicated patients in the GCE group had a lower fasting blood glucose (FBG) concentration compared to the placebo group; however, this decreasing was marginally significant (8.48 ± 8.41 vs. 1.70 ± 5.82 mg/dL, p = 0.05). There was no significant difference in insulin levels and HOMA-IR between the groups. At the end of the study, significant changes in systolic blood pressure (SBP) (p = 0.01), triglyceride (TG) level (p = 0.02), high-density lipoprotein (HDL) (p = 0.001), and TG-to-HDL ratio (p = 0.001) were found between the intervention and placebo groups. Our trial indicated GCE supplementation had no effect on diastolic blood pressure (DBP), low-density lipoprotein (LDL), or total cholesterol. During the supplementation period, the hs-CRP level significantly decreased in the GCE group compared to the placebo group (p = 0.02). No significant changes were observed in the MDA level between the two groups at the end of the study (p = 0.54).ConclusionOur findings showed beneficial effects of GCE on SBP, TG, hs-CRP, and HDL levels in patients with T2D and overweight/obesity over a 10-week period of supplementation.Clinical trial registration:https://en.irct.ir/trial/48549, identifier [IRCT20090203001640N18].

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of green coffee aqueous extract supplementation on glycemic indices, lipid profile, CRP, and malondialdehyde in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial

Khalili-Moghadam,

Hedayati,

Golzarand

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

show abstract

“…Y1R expression was upregulated by 17β-estradiol and downregulated by the anti-estrogen agent fulvestrant in breast cancer cells (MCF-7), whereas tamoxifen induced the total loss of Y1R in MCF-7 xenografts [ 104 ]. Supplementation with decaffeinated green coffee extract in breast cancer survivors with obesity did not affect serum NPY levels [ 105 ]. However, social isolation increased the risk of cancer development and NPY levels [ 106 ], and in an experimental model of breast cancer, chronic stress increased the extent/frequency of bone metastases [ 107 ].…”

Section: Involvement Of Neuropeptide Y Peptide Yy and Pancreatic Poly...mentioning

confidence: 99%

Neuropeptide Y Peptide Family and Cancer: Antitumor Therapeutic Strategies

Sánchez

Rodríguez

Coveñas

2023

IJMS

View full text Add to dashboard Cite

Currently available data on the involvement of neuropeptide Y (NPY), peptide YY (PYY), and pancreatic polypeptide (PP) and their receptors (YRs) in cancer are updated. The structure and dynamics of YRs and their intracellular signaling pathways are also studied. The roles played by these peptides in 22 different cancer types are reviewed (e.g., breast cancer, colorectal cancer, Ewing sarcoma, liver cancer, melanoma, neuroblastoma, pancreatic cancer, pheochromocytoma, and prostate cancer). YRs could be used as cancer diagnostic markers and therapeutic targets. A high Y1R expression has been correlated with lymph node metastasis, advanced stages, and perineural invasion; an increased Y5R expression with survival and tumor growth; and a high serum NPY level with relapse, metastasis, and poor survival. YRs mediate tumor cell proliferation, migration, invasion, metastasis, and angiogenesis; YR antagonists block the previous actions and promote the death of cancer cells. NPY favors tumor cell growth, migration, and metastasis and promotes angiogenesis in some tumors (e.g., breast cancer, colorectal cancer, neuroblastoma, pancreatic cancer), whereas in others it exerts an antitumor effect (e.g., cholangiocarcinoma, Ewing sarcoma, liver cancer). PYY or its fragments block tumor cell growth, migration, and invasion in breast, colorectal, esophageal, liver, pancreatic, and prostate cancer. Current data show the peptidergic system’s high potential for cancer diagnosis, treatment, and support using Y2R/Y5R antagonists and NPY or PYY agonists as promising antitumor therapeutic strategies. Some important research lines to be developed in the future will also be suggested.

show abstract

Adipo-oncology: adipocyte-derived factors govern engraftment, survival, and progression of metastatic cancers

Sato

2024

Cell Commun Signal

View full text Add to dashboard Cite

Conventional therapies for metastatic cancers have limited efficacy. Recently, cancer therapies targeting noncancerous cells in tumor microenvironments have shown improved clinical outcomes in patients. However, further advances in our understanding of the metastatic tumor microenvironment are required to improve treatment outcomes. Adipocytes are distributed throughout the body, and as a part of the metastatic tumor microenvironment, they interact with cancer cells in almost all organs. Adipocytes secrete various factors that are reported to exert clinical effects on cancer progression, including engraftment, survival, and expansion at the metastatic sites. However, only a few studies have comprehensively examined their impact on cancer cells. In this review, we examined the impact of adipocytes on cancer by describing the adipocyte-secreted factors that are involved in controlling metastatic cancer, focusing on adipokines, such as adiponectin, leptin, visfatin, chemerin, resistin, apelin, and omentin. Adipocyte-secreted factors promote cancer metastasis and contribute to various biological functions of cancer cells, including migration, invasion, proliferation, immune evasion, and drug resistance at the metastatic sites. We propose the establishment and expansion of “adipo-oncology” as a research field to enhance the comprehensive understanding of the role of adipocytes in metastatic cancers and the development of more robust metastatic cancer treatments.

show abstract

Effects of decaffeinated green coffee extract supplementation on anthropometric indices, blood glucose, leptin, adiponectin and neuropeptide Y (NPY) in breast cancer survivors: a randomized clinical trial

Abstract: Objective: The aim of this study was to evaluate the effects of decaffeinated green coffee extract (DGCE) supplementation on anthropometric indices, blood glucose, leptin, adiponectin and Neuropeptide Y (NPY) in...

Cited by 4 publications

References 57 publications

Effects of green coffee aqueous extract supplementation on glycemic indices, lipid profile, CRP, and malondialdehyde in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial

Effects of green coffee aqueous extract supplementation on glycemic indices, lipid profile, CRP, and malondialdehyde in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial

Neuropeptide Y Peptide Family and Cancer: Antitumor Therapeutic Strategies

Adipo-oncology: adipocyte-derived factors govern engraftment, survival, and progression of metastatic cancers

Contact Info

Product

Resources

About